PD‐0332991, a CDK4/6 inhibitor, enhances therapeutic outcomes by disrupting cell cycle regulation in tumor cells, particularly those lacking TP53‐mediated apoptosis and repair [79]. Here, CDK4 is linked to neoplasm.